HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

AbstractOBJECTIVE:
To review the literature on novel immunomodulators such as tumor necrosis factor alpha (TNF-alpha)- and interleukin (IL)-related agents, 6-thioguanine (6-TG), tacrolimus, and leflunomide, and antibiotics such as ornidazole, rifaximin, and ciprofloxacin for the treatment of Crohn's disease.
DATA SOURCES:
Literature was accessed through MEDLINE (1966-January 2006) using the terms Crohn's disease, novel therapies, immunomodulators, and antibiotics. Article references were hand-searched for additional relevant articles and abstracts.
STUDY SELECTION AND DATA EXTRACTION:
All articles in English identified from the data sources were evaluated. Studies including greater than 5 patients with primarily adult populations were included in the review.
DATA SYNTHESIS:
There are a number of new TNF-alpha and IL-related agents that may be useful for management of Crohn's disease. They include CDP 571, CDP 870, etanercept, onercept, thalidomide, IL-10, and IL-11. Several studies have shown that CDP 571 decreases the Crohn's Disease Activity Index score and is promising, especially in patients with refractory disease. 6-TG, tacrolimus, and leflunomide are among other immunomodulators that appear to have a role in refractory/severe disease. Finally, ornidazole, rifaximin, and ciprofloxacin are antimicrobials that may be used in patients who have failed other therapies or as adjunctive therapies.
CONCLUSIONS:
A number of new treatment modalities are being investigated for Crohn's disease. Many of them are promising, and some of these agents may be considered in treatment-refractory patients in the future. However, some of the agents reviewed here are not available in the US. Future studies need to be double-blinded and placebo- or other treatment-controlled in a more homogeneous patient population.
AuthorsSheila M Wilhelm, Jason D Taylor, Lisa L Osiecki, Pramodini B Kale-Pradhan
JournalThe Annals of pharmacotherapy (Ann Pharmacother) Vol. 40 Issue 10 Pg. 1804-13 (Oct 2006) ISSN: 1542-6270 [Electronic] United States
PMID16985094 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
  • Immunologic Factors
Topics
  • Animals
  • Anti-Bacterial Agents (therapeutic use)
  • Crohn Disease (drug therapy, epidemiology)
  • Humans
  • Immunologic Factors (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: